SynthesisScientific reports2025
In vitro and in silico studies and a systematic literature review of antiglycation properties of amlodipine.
Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Oxidative Stress, Pro-Inflammatory Response, Cytotoxicity and Apoptosis Induced by Contemporary Endodontic Sealers in Human Periodontal Ligament Fibroblasts.Journal of functional biomaterials · 2026Article
- Antiglycative Properties of Anti-Dementia Drugs-In Vitro, In Silico Studies and a Systematic Literature Review.Antioxidants (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Protein glycation is crucial in the pathogenesis of diabetes and its cardiovascular complications. Little is known about the antiglycation properties of amlodipine, a long-acting calcium channel blocker used to treat high blood pressure. In our study, amlodipine's antiglycoxidant activity was assayed in sugars (glucose, fructose, and ribose), aldehydes (glyoxal), and chloramine T-modified bovine serum albumin (BSA). Aminoguanidine and N-acetylcysteine were used as standard glycation/oxidation inhibitors. The content of oxidation, glycoxidation, and glycation protein products was measured colorimetrically and fluorimetrically. A one-way analysis of variance (ANOVA) followed by Tukey's post hoc test was used for statistical analysis. The mechanism of amlodipine's antiglycoxidant activity was also evaluated using in-silico molecular docking. Amlodipine protects against BSA oxidation, as evidenced by enhanced total thiol content and mitigated protein carbonyls/advanced oxidation protein products. Amlodipine also increased the fluorescence of tryptophan and decreased the contents of kynurenine, N-formylkynurenine, and dityrosine. In addition, amlodipine effectively prevents protein glycation, as evidenced by a reduction in amyloid-beta structure, Amadori products, and advanced glycation end products (AGEs). In in silico analysis, amlodipine's antiglycation properties were indicated during its interaction with BSA, glycosidases, and AGEs/receptor for AGEs (RAGE) pathway proteins. Among all proteins, amlodipine docked best with c-Jun N-terminal kinases. Summarizing, we have demonstrated the anti-glycation and antioxidant activity of amlodipine in vitro. This effect may be particularly important in patients with diabetes and atherosclerosis, where excessive glycation accelerates the development of vascular complications. Further studies are needed to confirm the antidiabetic activity of amlodipine in vivo.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.